Visfatin mediates malignant transformation of endometrium in PCOS patients through PI3K-Akt and MAPK-ERK signaling pathways (17), which leads to a higher prevalence of endometrial cancer in PCOS patients compared to other women in reproductive age. Here, AKT1 is linked to polycystic ovary syndrome.